Category Archives: Work

zoom
Summer-Recap-Looking-Ahead
-

OncoSec Summer Wrap-Up and Future Outlook

As the summer comes to an end, school begins, and the cool weather starts to set in, we wanted to share a recap of OncoSec’s milestones over the past few busy and exciting months.

Continue reading

zoom
NASDAQ
-

OncoSec Rings Nasdaq Opening Bell

We were thrilled to participate in the Nasdaq Opening Bell Ceremony to celebrate our recent listing to The Nasdaq Capital Market. This marks an exciting and significant milestone for our company as we continue to build on our success and advance our technologies to one day benefit patients everywhere.

Continue reading

zoom
san-diego-business-journal-logo
-

Upward and Onwards: OncoSec Moves to The NASDAQ Capital Market

On May 27th, we proudly announced that our common stock has been listed on The NASDAQ Capital Market. We’re very excited to be following an upward trajectory and expect this milestone will bring several benefits to the company, ranging from appealing to a broader set of investors to increasing the visibility of OncoSec’s capabilities.

Continue reading

zoom
logov3
-

Cancer immunotherapy is providing options for patients who are out of options

Established in 2011 by Punit Dhillon, OncoSec Medical Inc. is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through its proprietary technology, OncoSec aims to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.

Continue reading

zoom
An Introspective on Immunotherapy
-

An Introspective on Immunotherapy

This Tuesday, the OncoSec team will play host to some of the most brilliant minds in immuno-oncology, with our highly anticipated symposium, “An Introspective on Immunotherapy: A Symposium on Intratumoral Therapy.” The event promises to be a notable high point during the week of J.P. Morgan’s annual healthcare conference, a week that has historically attracted the “who’s who” of the healthcare sector.

Continue reading

zoom
Combination Trial Hope
-

OncoSec, UCSF, and Merck Initiate a Landmark Phase IIb Combination Trial of Breakthrough Drug KEYTRUDA® And ImmunoPulse to Treat Metastatic Melanoma

OncoSec Medical is changing the cancer experience. Today changes the course of OncoSec as we announced a collaboration with the University of California San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of Merck’s anti-PD-1 drug, KEYTRUDA® (pembrolizumab), and OncoSec’s ImmunoPulse therapy (intratumoral IL- 12), in a phase II metastatic melanoma study with patients non-responsive to KEYTRUDA®.  

Continue reading